摘要
目的观察PKC zeta在肝癌细胞株Bel-7402细胞中的表达及其在趋化运动中的作用,为PKC zeta在临床肝癌的治疗和预后评价中的应用提供实验依据。方法免疫组化染色,检测PKC zeta在肝癌细胞株Bel-7402细胞中的表达情况;四甲基偶氮唑蓝(MTT)检测,观察经PKC zeta抑制剂处理后肝癌细胞株Bel-7402不同时间和不同药物浓度的生长增殖情况;划痕实验观察PKC zeta抑制剂处理前后细胞在不同时间段的迁移距离;黏附实验观察PKC zeta抑制剂处理前后肝癌细胞Bel-7402在盖玻片上黏附细胞的数量差别;趋化实验观察PKC zeta抑制剂处理前后肝癌细胞Bel-7402在趋化因子影响下穿过8μm微孔滤膜细胞数的差异。结果 PKC zeta蛋白在肝癌Bel-7402细胞胞质中呈阳性表达;经药物处理的细胞一定时间内,迁移距离缩小,黏附细胞数量减少,趋化穿膜的细胞数也减少,差异具有显著性(P<0.05)。结论 PKC zeta在肝癌细胞株Bel-7402中阳性表达,且若抑制PKC zeta的表达能降低细胞侵袭转移能力。
Purpose To observe the expression of PKC zeta on Bel-7402 cells and the role in the cell chemotaxis,in order to provide an experimental basis in clinical treatment and prognosis evaluation.Methods The expression of PKC zeta in Bel-7402 cells was analyzed by immunocytochemistry.MTT assay was used to observe the inhibitory effects of PKC zeta inhibitor on Bel-7402 cells at various concentrations and different time points.Wound healing assay was used to observe migration distances of the cells in different periods.Chemotaxis assays were done to test the chemotaxis effect of PKC zeta inhibitor.Adhesion assay was carried out to detect the adhesion ability.Results Immunohistochemical results showed that PKC zeta protein was positive expression in cytoplasm;The distances were reduced in wound healing assay and the number of cells decreased in adhesion and chemotaxis assays after being treated by PKC zeta inhibitor(P0.05).Conclusions PKC zeta protein is positively expressed in Bel-7402 cells.By inhibiting the expression of PKC zeta,the cancer cell invasion and metastasis can be reduced.
出处
《临床与实验病理学杂志》
CAS
CSCD
北大核心
2011年第4期396-399,共4页
Chinese Journal of Clinical and Experimental Pathology
基金
国家自然科学基金(81072068)